GH Research (GHRS) Cash from Financing Activities (2021 - 2025)
GH Research (GHRS) recorded quarterly Cash from Financing Activities of -$68000.0 in Q4 2025, down 3.03% quarter-over-quarter from -$66000.0 in Q3 2025, and down 15.25% on a YoY basis from -$80240.0 in Q4 2024.
GH Research (GHRS) Cash from Financing Activities (2021 - 2025) Analysis & Trends
GH Research's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$68000.0 for Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 15.25% year-over-year to -$68000.0; the TTM figure through Dec 2025 stood at $139.7 million (up 46037.83% YoY), while the FY2025 annual figure was $139.7 million, up 46037.83% from the prior year.
- Cash from Financing Activities was -$68000.0 for Q4 2025 at GH Research, down from -$66000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $286.6 million in Q4 2022 to a low of -$2.6 million in Q3 2021.
- Historically, Cash from Financing Activities has averaged $32.7 million across 5 years, with a median of -$68000.0 in 2025.
- Biggest YoY gain for Cash from Financing Activities was 198491.55% in 2025; the steepest drop was 841.23% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at -$171000.0 in 2021, then jumped by 167712.87% to $286.6 million in 2022, then tumbled by 100.02% to -$70000.0 in 2023, then climbed by 15.71% to -$59000.0 in 2024, then fell by 15.25% to -$68000.0 in 2025.
- The last three Cash from Financing Activities figures came in at -$68000.0 (Q4 2025), -$66000.0 (Q3 2025), and -$1.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 85,464.43 |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | -68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68,000.00 |
| Dec 31, 2025 | -68,000.00 |
| Sep 30, 2025 | -66,000.00 |
| Sep 30, 2025 | -66,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 140.86 Mn |
| Mar 31, 2025 | 140.86 Mn |
| Dec 31, 2024 | -59,000.00 |
| Dec 31, 2024 | -59,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Sep 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -114,000.00 |
| Jun 30, 2024 | -114,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2024 | -71,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Mar 31, 2023 | -70,000.00 |
| Dec 31, 2022 | 286.62 Mn |
| Dec 31, 2022 | 286.62 Mn |